The USPTO’s Patent Trial and Appeal Board has ruled in favor of the Broad Institute of MIT and Harvard retaining intellectual property rights covered by its patents for CRISPR gene-editing technology.
July 25, 2001|
The retinoblastoma protein (pRB) is a tumor suppressor protein that can act as a transcriptional repressor, but the mechanisms underlying this function are unclear and controversial. In the July 17 Proceedings of the National Academy of Sciences, Kennedy et al., from the Massachusetts General Hospital Cancer Center, describe the use of a yeast model system to address the mechanism of pRB repression (Proc Natl Acad Sci USA 2001, 98:8720-8725). They expressed a chimeric protein in which the large